What's Happening?
IDB Invest has announced a financing package of up to $10 million for Ancalmo S.A. de C.V., a Salvadoran pharmaceutical company. The funding will be used to expand and modernize Ancalmo's production facilities, enhance manufacturing capacity, and strengthen
operations in El Salvador. The project aims to boost local pharmaceutical production, increase export capacity, and generate employment. The financing includes a committed tranche of $8 million and an uncommitted tranche of $2 million, with a term of up to 11 years.
Why It's Important?
This investment underscores IDB Invest's commitment to supporting strategic sectors like pharmaceuticals in Latin America. By enhancing Ancalmo's production capabilities, the financing is expected to strengthen the company's competitive position in regional markets, including Central America, the Caribbean, and Mexico. The project will also foster economic growth by creating jobs and strengthening supply chains with local suppliers. Additionally, IDB Invest will provide technical assistance to improve corporate governance and explore energy self-supply solutions, further enhancing the company's sustainability.
